News

Galapagos’ GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study

Date: 22/11/2011

Mechelen, Belgium – Galapagos reports that its JAK1 inhibitor GLPG0634 shows excellent efficacy and safety in a Phase II clinical study in rheumatoid arthritis patients. See the press release here.